IE61165B1 - Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation - Google Patents

Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation

Info

Publication number
IE61165B1
IE61165B1 IE86988A IE86988A IE61165B1 IE 61165 B1 IE61165 B1 IE 61165B1 IE 86988 A IE86988 A IE 86988A IE 86988 A IE86988 A IE 86988A IE 61165 B1 IE61165 B1 IE 61165B1
Authority
IE
Ireland
Prior art keywords
hydrogen
carbon atoms
alkyl
halogen
compound
Prior art date
Application number
IE86988A
Other versions
IE880869L (en
Inventor
Torbjorn Erik Lundstedt
Knut Gunnar Olsson
Tomas Fex
Aina Lisbeth Abramo
Erik Gunnar Cristensson
Original Assignee
Leo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Ab filed Critical Leo Ab
Publication of IE880869L publication Critical patent/IE880869L/en
Publication of IE61165B1 publication Critical patent/IE61165B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

PCT No. PCT/SE88/00144 Sec. 371 Date Nov. 30, 1988 Sec. 102(e) Date Nov. 30, 1988 PCT Filed Mar. 25, 1988 PCT Pub. No. WO88/07528 PCT Pub. Date Oct. 6, 1988.A compound having the formula (I) or a pharmaceutically acceptable salt thereof: <IMAGE> wherein all the symbols are defined in the specification; having valuable pharmaceutical properties, useful for the treatment of mental disorders, such as psychoses, depression and anxiety.

Description

There is am urgent need for novel drugs in the treatment of mental disorders which are more effective and which have fewer side effects than the drugs in clinical use today. Antipsychotic crags in current use produce a range of troublesome extrapyramidal movement disorders (e.g. acute dystonic reactions and tardive dyskinesia) and are poor in ameliorating the negative symptoms (e.g. restricted or blunted emotional arousal) of schizophrenia.
The main disadvantage of the antidepressants is that they fail to alleviate depression in 30 to 40 % of patients. Anxiolytics are commonly associated o with addictive properties.
Prior art Various pyridyl- and pyrimidyl-piperazine derivatives pharmacologically active in the central nervous system are known in the art. Some representative examples can be mentioned. Azaperone, a neuroleptic drug of the butyrophenone series, is a sedative for pigs. Buspirone is an anxiolytic. The anxiolytic effect is thought to be mediated via effects on the 5HTreceptors. azaperone Compounds structurally similar to the present compounds are disclosed in DE-A 3507983. This document discloses compounds which differ from the compounds according to the present invention essentially by the presence of an OH-group instead of an H substituent on the diphenyl bearing carbon atom of the present compounds. It is, however, very clear from this document that the by far most preferred and only tested compound is MJ 14802. This compound differs from the present compounds not only as regards the OH substituent but also in that it carries only one phenyl ring, whereas our compounds carry two phenyl rings. Additionally, it is known and published by Largent et al in the European Journal of Pharmacology, 1055, 1988, pages 345-347 that MJ 14802 has essentially no affinity to 5HT2 receptors, whereas our compounds are distinguished by a high 5 HT2 receptor binding affinity.
Description of the invention Pyridyl- and pyrimidyl-piperazines substituted in the 4-position of the piperazine ring with a highly lipophilic diphenyl-butyl group have unexpectedly been found to exhibit pharmacological properties superior to compounds known in the art.
According to the invention there are provided novel compounds having the 2q general formula (I).
I wherein R^ and Rg are the same or different and selected from hydrogen and halogen; R3 and R4 are the same or different and selected from hydrogen and alkyl having 1 to 5 carbon atoms; n is 2 or 3; A is selected from the following pyrimidyl- or pyridyl-groups: 7Λ'6 \=Λ7 wherein R^ is selected from hydrogen, alkyl having 1 to 5 carbon atoms or halogen; Rfi and R-, are the same or different and selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups selected from alkoxy having 1 io 5 carbon atoms, or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoromethyl, COORg, COWR^R^ or COB; wherein Rg is hydrogen or alkyl having 1 to 5 carbon atoms; R^ and R.j0 are the same or different and selected from hydrogen, alkyl having 1 to 5 carbon atoms, and cycloalkyl having 3 to 8 carbon atoms: B is selected from -N sn I11 m -N · 0 \_/ wherein m is 1, 2, 3 or 4.
R,., is selected from hydrogen or alkyl having 1 to 5 carbon atoms, and the pharmacologically active salts thereof; and when used in the foregoing definitions the term alkyl is meant to include straight and branched hydrocarbon groups; the term alkojy is meant to include straight or branched alkoxy groups; the term halogen is meant to include fluoro, chloro and bromo. V It is preferred that one of R1 and R, is different from hydrogen and when one or both of Ft and R-, are halogen fluoro is preferred.
As regards R3 and Ft hydrogen or methyl are preferred, especially hydrogen.
As regards Rg hydrogen, methyl or halogen, especially fluoro, is preferred.
As regards R6 hydrogen, methyl, alkoxy, amide, nitro, mfluoromethyl, halogen or cyano is preferred.
It is preferred that R?, is hydrogen, methyl, alkoxy, nitro, halogen, cyano or an amide group.
Compounds wherein A is 2-substituted pyridyl are of special interest, especially those carrying an methoxy, amide, cyano or hydrogen substituent in the 3-position.
The compounds of formula (I) have basic properties and, consequently, they may be converted to their tlierapeuticaJly active add addition salts by treatment with appropriated adds; e.g. Inorganic adds such as hydrochloric, hydrobromic, sulfuric, nitric and phosphoric add, or organic adds such as acetic, propanoic, glycolic, lactic, malonic, oxalic, succinic, fumaric, tartaric, citric and narnoic add.
I Conversely, the salt form can be converted into the free base form by treatment with alkali.
The compounds of formula (ϊ) and their pharmaceutically acceptable salts have valuable pharmacological properties, making them useful for the treatment of mental disorders such as psychoses, depression and anxiety. Stress and anxiety in animals can also be treated.
It has been assumed that the antipsychotic actions of neuroleptic drugs ar e inextricably linked to their ability to produce extrapyramidal side-effects, possibly by an action at a common site. This assumption is now being questioned since antipsychotic drugs nowadays exist with a reduced potential to produce these side-effects. Thus, it is thought that the two main actions of classical neuroleptic drugs, i.e. antipsychotic action and ability to produce extrapyramidal syndromes, are mediated by actions at different sites in the brain. The neuroleptic drugs may produce their therapeutic antipsychotic effects by an action on the mesolimbic system. On the other hand, since the main function of the nigrostriatal dopaminergic pathway is the control of motor performance, this site in the brain is usually assumed to be the region where the neuroleptic drugs produce their extrapyramidal side-effects. Experimentally, inhibition of amphetamine induced hypermotility in rodents measures the limbic effect whereas it is generally accepted that the ability of neuroleptics to induce catalepsy in rodents correlates well with the risk of extrapyramidal side-effects.
The compounds of the present invention show neuroleptic properties since they affect amphetamine-induced hypermotility, but show weak or no cataleptogenic activity. They show a high affinity for D2 and 5-HT2 receptors in the brain. A high 5HT2-receptor binding affinity may indicate antidepressant properties, since many antidepressants (e.g. amitriptyline) are potent 5HT,-blockers. A high 5HT,-receptor binding affinity also suggests anxiolytic properties. A novel anxiolytic, ritanserine, labels preferentially the -HT2 binding site.
Effective quantities of any of the foregoing pharmacologically active compounds of formula (I) may be administered to a human being or an animal for therapeutic purposes according to usual routes of administration and in usual forms, such as orally in solutions, emulsions, suspensions, pills, tablets and capsules, in pharmaceutically acceptable carriers and parenterally in the form of sterile solutions. For the parenteral administration of the active substance the carrier of excipient may be a sterile, parenterally acceptable liquid, e.g. water, or a parenterally acceptable oil, e.g. arachidic oil.
Although very small quantities of the active materials of the present 10 invention are effective when minor therapy is involved or in the cases of administration to subjects having a relatively low body weight, unit dosages are usually from 2 milligrams upwards, preferably 10, 25 or 50 milligrams or even higher depending on the condition to be treated and the age and weight of the patients as well as the response to the medication.
The unit dose may be from 0.1 to 100 milligrams, preferably from 10 to 50 milligrams. Daily dosages should preferably range from 10 milligrams to 200 milligrams. The exact individual dosages as well as daily dosages will, of course, be determined according to standard medical principles under the direction of a physician or veterinarian.
Methods of nreuaration.
The compounds having the general formula (I) may be prepared by 25 conventional methods.
Method 1 I A compound of formula (II), wherein R, and R? are as previously defined and Y is a suitable leaving group such as halogen and alkyl· or arylsulfonate is reacted with a compound of formula (ΓΠ) wherein R3, R, A and n are as defined previously. The reactions may be carried out using standard NS alkylating procedures.
Method 2 A compound of formula (FV), wherein R^, RSs R, and n are as previously defined is reacted with a compound of formula Cv): (VI), (VH) or (VUI), wherein Rg, R^ and R~ are as previously defined and Z is a leaving group, e.g. halogen.
Exawles The following examples are intended to illustrate the invention, the compounds named are of particular interest for our intended purposes. These compounds have been designated by s. number code, a:b, where a means the number of the example, wherein the preparation of the compound in question is described, and b refers to the order of the compounds prepared according to that example. Thus, compound 1:2 means the second compound prepared according to Example 1.
The structures of the compound are confirmed by NMR, masspectra and elementary analysis. When melting points are given, these are uncorrected.
Example 1 5 4- r4.4-bis(p-fluorophenvl)butvl,]°l-(5-chloro-2-pyridvl)-piperazine dihydroehloride 19.8 g (0.06 mole) of l-[ 4,4-bis(p-fluorophenyl)butyl,]piperazine and 2.96 g (0.02 mole) of 2,5-dicMoropjridine were heated together with 2 ml of toluene at 130°C (temperature of oil bath) for 20 h.
After cooling die reaction mixture was partitioned between ligroin and MeOH/H2O (3:1). The MeOH/H2O phase was extracted an additional time IS with ligroin and the collected ligroin phases were dried with Na2SO4.
Evaporation of the solvents yielded crude free base, which was dissolved in ether and the hydrochloride was precipitated with excess HCl in EtOH. Reciystallization from EtOAc/EtOH yielded 4.3 g (42 %) of the title compound (1:1), m.p. 173-6 °C.
Using essentially the same procedure the following compounds were prepared (isolated as the free bases or as the corresponding salts) from the corresponding starring materials. 1:2 4- [4,4-bis(p-fluorophenyl)butyl]-l~(6-methyl-2"pyridyl)-piperazine oxalate, m.p. 172-4° c. 1:3 4- [4,4-bis(p-fiuorophenyl)butyl]-l-(6-methoxy-2-pyridyl)-piperazine fumarate, m.p. 175-7°C. 1:4 4. [4,4-bis(p-fluorophenyl)butyl] l-(3-trifruoro-memyl-2-pyridyl)30 piperazine, monohydrochloride isopropanol, m.p. 94-95°C (sintered) 1:5 4- [4,4-bis(p-fluorophenyl)butyl] -l-(5-trixluoro-inethyi-2-pyridyi)~ piperazine monohydrochloride, m.p. 197-9°C 1:5 4- [4,4-bis(p-fluorophenyl)butyl }-l-(3-carbamoyl-2-pyridyl)piperazine dihydrochloride, m.p. 208-10 °C 1:7 4- [4,4-bis(p-fluorophenyl) butyl] -1 -(5-carbamoyl-2-pyridyl)-piperazine dihydrochloride, m.p. 250 6 C 1:8 4- [4,4-bis(p-fluorophenyi)butyU -1 - [3-(N-methyi-carbamoyl)-2pyridyl]-piperazine dihydrochloride d. 185®C 1:9 4- [4,4-bis(p-fluorophenyl)butyl] -1- [3-(M,N-dimethyl-carba«toyl)-2" pyridyl 1-piperazine fumarate m.p. 182-3°C 1:10 4- [4,4-bis(p-fluorophenyl)butyl]-l-(3-motpholjino-carbonyl-2-pyridyl)piperazine oxalate m.p. 183-5 ®C 1:11 4- [4,4-bis(p-fluorophenyi)butyl] -1 -(3-pyrrolidino-carbon^-2-pyridyl) piperazine fumarate m.p. 194-5°C 1:12 4- [4,4-bis(p-fluorophenyl)butyl ] -1 -(3-cyano-2-pyridyl)piperazine oxalate m.p. 180-1® C 1:13 4- [4,4-bis(p-fluorophenyi)butyl ] -l-(3-nitro-2-pyiidyl)-piperazine monohydrochloride, nap. 147-8°C 1:14 4- [4,4-bis(p-fluorophenyl)butyl]-l-(S-nitro-2-pyiidyl)-piperazine hydrochloride m.p.' 214-6°C 1:15 4- [4,4-bis(p-fluorophenyl)butyl]-l-(2-pyridyl)-(l,4-diazacycloheptane) x 2.5 oxalate m.p. 115-8°C 1:16 4- [4,4-bis(p-fluorophenyl)butyl]-l-(2-pyridyl)-trans-2,5dimethylpiperazine oxalate xn.p. 141-2®C 1:17 4- [4,4-bis(p-fluorophenjd)bwtyl ] -1 - [ 2-(methyl-pyridine-5-carboxylaie) yi] piperazine dihydrochloride ethanol m.p. 153 °C (sintered) 1:18 4- [4,4-bi$(p-fluoropheayl)butyl]-l-(4-pyridyl)-piperazine difumarate m.p. 191-2°C 1:19 4- [4,4-bis(p-fluorophenyl)butyl ]-l-(3-methyi-2-pyridyl piperazine dihydrochloride hemi-isopropanol m.p. 207-9 "C 1:20 4- [4,4-bis(p-fluorophenyl)butyl ]-1 -(3-medioxy-2-pyridyl)-piperazme oxalate d. 187-8 "C 1:21 4- [4,4-bis(p-fluorophenyl)butyil -l-(5-chloro-2-pyridyl)-piperazine hydrochloride m.p. 172-3 °C S 0 1:22 4- [4,4-bis(p-fluorophenyl)butyl] -1 -(3-chloro-2-pyridyl)-piperazine fumarate m.p. 145-6°C 1:23 4- [4,4-bis(p-fiuorophenyI)butyl] -1 -(3-carboxy-2-pyri.dyl)-piperazine dihydrochloride ethanol mp. 185°C (sinters) m.p. 210°C 1:24 4- [4,4-bis(p-fluorophenyl)butyiJ -l-[ 3-(4-meihyI-piperidinocarbonyl)-2pyridyl]-piperazine fumarate mp. 191-2°C 1:25 4- [4,4-bis(p-fluorophenyl)butyl ]-1 -(3-carbamyl~2-pyridyl)-l,4diazacycloheptane dihydrochloride hemihydrate mp. 176-79 ®C (sintered) 1:26 4- [4,4-bis(p-iluorophenyl)butyl]-l-(3-trifluoromethyi-6-chlorO"2pyiidyl)-piperazine hydrochloride mp. 141 -2 ®C 1:27 4- [4,4-bis(3,4-difluorophenyl)butyl] -l-(2-pyrid)d)-piperazine dihydrochloride, hydrate sap. 169-70°C 1:28 4- [4,4"bis(p-fluorophenyl)butyl ]-l~(3-hydroxy-2-pyridyl)-piperazine 1:29 4- [4,4-bis(p-fiuorophenyl)butyl ]-l-(3-pyridyl)-piperazine 1:30 4-[4,4-bis(p-fluorophenyl)butyl]-l-(3-carbamoyl-6-methyl-2-pyridyl)piperazine 1:31 4- [ 4,4-bis(p-fluorophenyl)bntyi]-l-(3-carbamoyl-6-chloro-2-pyridyl)piperazine 1:32 4- l4,4-bis(p-fluorophenyl)butyl ]-l-(4-methyl-2-pyridyl)-piperazine 1:33 4- [4,4-bis(p-fiuorophenyl)bu«yi l-l-(3-ethoxy-2-pyxidyl)-piperazine 1:34 4- [4,4-bis(p~fiuorophenyl)b«tyl] -l-(3-propozy-2-pyndyl)-piperazme 1:35 4- [4,4-bis(p-fluorophenyl)butyl ] -1 -(3>isopropoxy-2-pyxidyl)-piperazine 1:36 4- [4,4-bis(p-fluorophenyl)butyl] -l-(3-cydohexozy-2-pyridyl)piperazine IExample 2 4- t4.4-bis(p-fluoronhenyl)butyl 1-1 -(2-pyrimidvi)-piperazine hydrochloride 8.3 g (0.025 mole) of l-[4,4~bis(p-fluorophenyl)butyl] -piperazine and 3.1 g (0.027 mole) of 2-chloropyrimidin were heated in 5 ml DMF at 150°C until TLC showed, the disappearance of the starting piperazine derivative. After cooling EtOAc (50 ml) and EtOH (enough to get a dear solution) were added. Ether was added, whereby the desired product crystallized.
Recrystallisation from EtOH, EtOAc 4 ether yielded 7.3 g (65 %) of the tide compound (2:1), m.p. 195-97°C.
Example 3 ...
IS 4- i4.4-bis(p-fluorophenyl)butvll -1 -(2-pyridyD-piperazine dihydrochloride 3.3 g (0.01 mole) of l-chloro-4,4-bis(p-fluorophenyl)butane, 3.3 g (0.02 mole) of 1 -(2-pyridyl)-piperazine and 0.05 g of KI were refluxed in IS ml of toluene for 48 h. After cooling and addition of ether (30 ml) l-(2-pyridyl)piperazine hydrochloride precipitated and was filtered off. After subsequent washing several times with K,0 the organic layer was dried with 'K,CO3. Evaporation of the solvent yielded the crude base. This was dissolved in ether and HO in EtOH was added to precipitate the hydrochloride.
Recrystallization from EtOAc/EtOH yielded 3.2 g (67 %) of the title compound (2:1), m.p. 224-27 ®C. using essentially the same procedure the following compounds are prepared (isolated as the free bases or as the corresponding salts) from the corresponding starting materials. 3:2 4- [4,4-bis(p-fluorophenyl)butyll-l-(5-fluoro-2-pyrimidyl)-piperazine Example 4 This example illustrates the potency of compounds of formula (Ϊ) and their pharmaceutically active salts for treatment of mental disorders.
Test 1 - Antagonism of amphetamine-induced hvpermotility in mice A low dose (2 mg/kg) of d-amphetamine administered to mice induced pronounced locomotor activity.
Test procedure Female NMRI-mice, weighing about 25 g are divided into groups of 4 animals and placed in macrolon cages. The cages are placed on recording arenas in nine sound attenuated boxes with constant light and ventilation.
After a familiarization period of 90 minutes the mice are brought up from the cages and treated in the following way; one control group receives saline i.p., one control group receives d-amphetamine sulphate, 2 mg/kg i.p. and test animals are treated s.c. with three different doses of the test compound and immediately thereafter with d-amphetamine 2 mg/kg i.p.. Immediately after the administration the macrolon cages with the mice are put back into me test boxes and a computerized equipment records the locomotor activity an the cages for 90 minutes.
For each test compound 4 cages are treated with saline, 4 cages with only damphetamine and 6 cages/dose test compound + d-amphetamine. This is the total of three different experiments.
Data analysis For each treatment group die mean number of counts during 90 minutes following the administration is calculated. 3 The ED5£fvalue (mg/kg) is calculated from the dose-response curve by means of linear regression. The EDS0-value represents a dose of test compound reducing the motility to the midpoint between amphetamine and saline controls.
Test 2 - Affinity to Preceptors The binding assay is carried out essentially as described by Leysen et al., (Mol. Pharmacol. 21, 301-14, 1982) using ^-spiroperidol as ligand. 1C Test 3 - Affinity to 5HT2-receptors The binding assay is carried out essentially as described by Leysen et al., (Mol. Pharmacol. 21, 301-14, 1982) using 3H-ketanserine as ligand.
TABLE 1 Antagonism of amphetamine induced hypermotility in mice Compound ED50 mg/kg s.c. 3:1 0.1 1:6 0.3 TABLE 2 Compound 3:1 1:6 1:15 Affinity to Ρ-,-receptors Ki fnM) TABLES Compound 3:1 1:6 1:15 Affinity to 5h i ,-receptors Ki (nM) .8 2.1 1.3 Λ ΐ’ 4 The compounds listed in table 1, 2 and 3 are given to exemplify the useful pharmacological activities of compounds within the scope of formula (I).
Example 5 The following formulations are representative for all of the pharmacologically active compounds of this invention. Example of a suitable capsule formulation: Per capsule, mg Active ingredient, as salt 10 Lactose 250 Starch 120 Magnesium stearate 5 Total 385 in case of higher amounts of active ingredient, the amout of lactose used may be reduced.
Example of a suitable tablet formulation: Per tablet, mg Active ingredient, as salt 10 Potato starch 90 Colloidal Silica 10 Talc 20 Magnesium stearate 2 5 % aqueous solution of gelatin Total 157 Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the Λ Ο active substance preferably in a concentration of from about 0.5 % to about 5 % by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit J ampoules.

Claims (10)

1. Compounds having the general formula (I) (I) wherein R 1 and Rg are the same or different and selected from hydrogen and halogen; R 3 and R, are the same or different and selected from hydrogen and alkyl having 1 to 5 carbon atoms n is 2 or 3; A is selected from the following pyximidyl- or pyridyl-groups: wherein Rg is selected from hydrogen, alkyl having 1 to 5 carbon atoms, or halogen; FC and axe the same or different and selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups selected from alkoxy having 1 to 5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoromethyl, COOIL, CONR 5 R 10 or CO-B; wherein. Rg is hydrogen or alkyl having 1 to 5 carbon atoms; R y and R 10 are the same or different and selected from hydrogen, alkyl having 1 to 5 carbon atoms and cycloalkyl having 3 to 8 carbon atoms; 2. 1 12. A method of preparing a compound having the formula (1) given and defined in claim 1 or a pharm- ecologically active salt thereof, substantially as hereinbefore described with particular reference 2 0 or wherein & compound having the general formula (IV) wherein R v Rj, Rj, R, and n are as previously defined, is reacted with a compound having the formula (V), (VI), (VH) or (VUI): Rg S Rj and R? are as previously defined and Z is a leaving group. 10. Pharmaceutical compositions containing as an active ingredient one or more of the compounds having die genera! formula (!), preferably together with a pharmaceutically acceptable carrier and, if desired, other pharmacologically active agents. 11. A compound having the general formula (J) given and defined in claim 1 or a pharmacologically active salt thereof, which is any one of those specifically hereinbefore mentioned.
2. Compounds according to claim 1 wherein one of FL, and IL, is halogen, preferably fluoro.
3. Compounds according to claim 1 or 2, wherein R 3 and R 4 are hydrogen or methvl, preferably hydrogen.
4. Compounds according to claim 1, 2 or 3, wherein A is 5. To Examples 1-3 of the accompanying Examples. 13. A compound having the formula (I) given and defined in claim 1 or a pharmacologically active salt thereof, whenever prepared by a method claimed in claim 9 or 12. 10 14. A pharmaceutical composition according to claim 5 8
5. Compounds according to claim 4, wherein R-, is hydrogen, methyl, trifluoromethyl, alkoxy having 1 to 5 carbon atoms, amide, nitro or cyano and K 7 is hydrogen, methyl, methoxy, nitro, halogen, cyano or an amide group. 5 7 B is selected from ), ), wherein m is 1, 2, 3 or 4; R 11 is selected from hydrogen or alkyl having 1 to 5 carbon atoms, and the pharmacologically active salts thereof.
6. Compounds according to claim 5, wherein R. is hydrogen, methyl, or trifluoromethyl and R» is alkoxy having 1 to S carbon atoms, nitro, halogen, cyano or an amide group and R ? is situated in the 3-position.
7. Compounds according to claim 6, wherein R 0 is hydrogen and R 7 is hydrogen, cyano, nitro, alkoxy having 1 to 5 carbon atoms or an amide substituent. 8. Is selected from N 0 5_/ wherein m is 1, 2, 3 or 4. R n is selected frcm hydrogen or alkyl having 1 to 5 carbon atoms and the pharmacologically active salts thereof, wherein a compound having the general formula (Π) IS II /2 chch 2 ch 9 ch 2 ~y wherein R 1 and Rg are as defined above and Y is a leaving group, is reacted with a compound having the general formula (III) Λ ·, 1¾ in wherein Rg, R 4 , n and A are as defined above
8. Compounds according to claim 7 wherein R 7 is an amide, hydrogen, cyano or methoxy substituent.
9. A method of preparing compounds having the general formula (I) (I) wherein R, and are the same or different and selected from hydrogen and halogen; Rg and R, are the same or different and selected from hydrogen and alkyl having 1 to 5 carbon atoms: π is 2 or 3; A is selected from the following pyrimidyl or pyridyl groups: wherein R- is selected from hydrogen, alkyl having 1 to 5 carbon atoms or halogen; R 0 and R 7 are the same or different and selected from hydrogen, halogen, alkyl having I to S carbon atoms, electron donor groups selected from alkoxy having 1 to 5 carbon atoms, or hydroxy, electron acceptor groups selected from cyano, nitro, trifluorcmethyl, COORg, OONR g R 10 or CO-Β; wherein R g is hydrogen or ί 9 alkyl having 1 to 5 carbon atoms; R^ and R 10 are the same or dhterent and selected from hydrogen, alkyl having 1 to 5 carbon atoms and cycloalkyl having 3 to 8 carbon atoms;
10. , substantially as hereinbefore described with particular reference to Example 5 of the accompanying Examples.
IE86988A 1987-04-02 1988-03-23 Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation IE61165B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8701375A SE8701375D0 (en) 1987-04-02 1987-04-02 NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES

Publications (2)

Publication Number Publication Date
IE880869L IE880869L (en) 1988-10-02
IE61165B1 true IE61165B1 (en) 1994-10-05

Family

ID=20368077

Family Applications (1)

Application Number Title Priority Date Filing Date
IE86988A IE61165B1 (en) 1987-04-02 1988-03-23 Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation

Country Status (18)

Country Link
US (1) US4937245A (en)
EP (1) EP0308476B1 (en)
JP (1) JPH0819104B2 (en)
KR (1) KR920003062B1 (en)
AT (1) ATE85334T1 (en)
AU (1) AU611147B2 (en)
CA (1) CA1321997C (en)
DE (1) DE3878111T2 (en)
DK (1) DK161313C (en)
ES (1) ES2006619A6 (en)
FI (1) FI92320C (en)
HU (1) HU201051B (en)
IE (1) IE61165B1 (en)
IL (1) IL85932A (en)
NO (1) NO172640C (en)
NZ (1) NZ224005A (en)
SE (1) SE8701375D0 (en)
WO (1) WO1988007528A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701375D0 (en) * 1987-04-02 1987-04-02 Leo Ab NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES
US5219855A (en) * 1988-01-29 1993-06-15 Mitsubishi Kasei Corporation Anxiolytic drug
JP2664238B2 (en) * 1989-03-01 1997-10-15 日清製粉株式会社 Nicotinic acid or its ester derivatives
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
SE9201239D0 (en) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab AGENTS FOR TREATING SUBSTANCE ABUSE DISORDERS
JPH0665203A (en) * 1992-06-25 1994-03-08 Elf Sanofi Heterocyclic derivative of piperazine
EP0580465A1 (en) * 1992-06-25 1994-01-26 Sanofi New therapeutic use of heterocyclic piperazines as 5-HT3 agonists and new derivatives
SE9201956D0 (en) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab NOVEL NICOTINICACID ESTERS
SE9202265D0 (en) 1992-07-31 1992-07-31 Kabi Pharmacia Ab NOVEL- PYRIDYL AND PYRIMIDYLPIPERAZINE DERIVATIVES
HU226859B1 (en) 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
KR20020005662A (en) 1999-04-09 2002-01-17 기따자또 이찌로 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2958694A (en) * 1959-06-22 1960-11-01 Janssen Paul Adriaan Jan 1-(aroylalkyl)-4-(2'-pyridyl) piperazines
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
US2979508A (en) * 1959-10-12 1961-04-11 Paul A J Janssen Heterocyclic derivatives of 1-phenyl-omega-(piperazine) alkanols
JPS6081167A (en) * 1983-10-11 1985-05-09 Sumitomo Chem Co Ltd Phenylacetone derivative and production thereof
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
JPS6175A (en) * 1984-03-06 1986-01-06 ブリストル−マイア−ズ　コムパニ− Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl) piperazine derivative
GB8603120D0 (en) * 1986-02-07 1986-03-12 Pfizer Ltd Anti-dysrhythmia agents
JPS63146872A (en) * 1986-07-08 1988-06-18 Yoshitomi Pharmaceut Ind Ltd Pyrimidinylpiperazine compound
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
SE8701375D0 (en) * 1987-04-02 1987-04-02 Leo Ab NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES

Also Published As

Publication number Publication date
KR920003062B1 (en) 1992-04-13
ES2006619A6 (en) 1989-05-01
DE3878111T2 (en) 1993-07-01
SE8701375D0 (en) 1987-04-02
US4937245A (en) 1990-06-26
JPH0819104B2 (en) 1996-02-28
IE880869L (en) 1988-10-02
NO885386D0 (en) 1988-12-02
AU611147B2 (en) 1991-06-06
DK161313B (en) 1991-06-24
FI92320B (en) 1994-07-15
FI885560A0 (en) 1988-11-30
AU1579688A (en) 1988-11-02
ATE85334T1 (en) 1993-02-15
NZ224005A (en) 1991-03-26
KR880012586A (en) 1988-11-28
NO172640C (en) 1993-08-18
IL85932A (en) 1993-05-13
IL85932A0 (en) 1988-09-30
FI92320C (en) 1994-10-25
WO1988007528A1 (en) 1988-10-06
HUT50325A (en) 1990-01-29
CA1321997C (en) 1993-09-07
JPH01502832A (en) 1989-09-28
DK671588D0 (en) 1988-12-01
DE3878111D1 (en) 1993-03-18
NO172640B (en) 1993-05-10
NO885386L (en) 1988-12-02
FI885560A (en) 1988-11-30
DK671588A (en) 1988-12-01
DK161313C (en) 1991-12-30
HU201051B (en) 1990-09-28
EP0308476B1 (en) 1993-02-03
EP0308476A1 (en) 1989-03-29

Similar Documents

Publication Publication Date Title
IE61165B1 (en) Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation
EP0361271B1 (en) Pyridyl- and pyrimidyl derivatives
EP0652867B1 (en) Novel pyridyl- and pyrimidylpiperazine derivatives
US5658910A (en) Nicotinic acid esters

Legal Events

Date Code Title Description
MM4A Patent lapsed